
Clinical-stage biotechnology company expects to raise approximately USD 317.5 million from the offering, with shares scheduled to begin trading on Nasdaq on October 23, 2026.
SOUTH SAN FRANCISCO, Calif., Oct. 22, 2026 — Lycia Therapeutics, Inc. (“Lycia”) (Nasdaq: LYCA), a clinical-stage biotechnology company developing novel therapeutics designed to degrade disease-causing extracellular proteins, today announced the pricing of its upsized initial public offering (IPO).
The offering comprises 17,640,000 shares of common stock at an initial public offering price of USD 18.00 per share. Gross proceeds are expected to total approximately USD 317.5 million, before deducting underwriting discounts and commissions and other offering expenses. All shares included in the offering are being sold by Lycia.
Lycia has also granted the underwriters a 30-day option to purchase up to an additional 2,646,000 shares of common stock at the IPO price, less applicable underwriting discounts and commissions.
The company’s common stock is expected to begin trading on the Nasdaq Global Select Market on October 23, 2026, under the ticker symbol “LYCA.” The offering is expected to close on October 26, 2026, subject to customary closing conditions.
Jefferies, TD Cowen, Evercore ISI, and Guggenheim Securities are serving as joint book-running managers for the offering. LifeSci Capital is acting as a passive book-running manager.
Registration Statement and Prospectus Information
Registration statements relating to the securities have been filed with the U.S. Securities and Exchange Commission (SEC) and became effective on October 22, 2026. The offering is being conducted exclusively through a prospectus.
When available, copies of the final prospectus may be obtained from the following underwriters:
- Jefferies LLC: Equity Syndicate Prospectus Department, 520 Madison Avenue, New York, NY 10022. Telephone: (877) 821-7388. Email: [email protected].
- TD Securities (USA) LLC: Attention: Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717. Email: [email protected].
- Evercore Group L.L.C.: Equity Capital Markets, 55 East 52nd Street, 35th Floor, New York, NY 10055. Telephone: (888) 474-0200. Email: [email protected].
- Guggenheim Securities, LLC: Equity Syndicate Department, 330 Madison Avenue, 8th Floor, New York, NY 10017. Telephone: (212) 518-9544. Email: [email protected].
This press release does not constitute an offer to sell or a solicitation of an offer to buy any securities of Lycia. No sale of these securities will be made in any state or jurisdiction where such an offer, solicitation, or sale would be unlawful before registration or qualification under the applicable securities laws. Any offers, solicitations, or sales of securities will be made in accordance with the registration requirements of the Securities Act of 1933, as amended.
About Lycia Therapeutics
Lycia Therapeutics is a clinical-stage biotechnology company focused on discovering and developing novel therapeutics designed to degrade disease-causing extracellular proteins. Its initial research and development focus includes autoimmune, inflammatory, and allergic diseases.
The company has developed its proprietary LYTAC (Lysosomal Targeting Chimera) platform to generate cataLYTAC degraders, which are designed to support the repeated catalytic elimination of disease-causing proteins.
Lycia’s lead candidates include LCA-0061, a cataLYTAC degrader of IgE being developed for food allergies and other allergic diseases, and LCA-0321, a LYTAC degrader designed to selectively deplete the autoantibodies responsible for Graves’ disease.
Headquartered in South San Francisco, Lycia was founded on the research of Nobel laureate Carolyn Bertozzi, Ph.D., professor of chemistry and Howard Hughes Medical Institute investigator at Stanford University.
Company Contact
Company Inquiries:
[email protected]
Media Contact:
Jennifer Price
The Grace Group
[email protected]

